Xeris Biopharma Holdings, Inc. reported total revenue of over $92 million for Q2 2026, reflecting a 29% year-over-year increase. With net product revenue up 34% to over $91 million, the company has tightened its full-year revenue guidance to between $385 million and $390 million, signaling strong operational momentum.

Key Highlights

  • Total revenue increased 29% year-over-year to over $92 million.
  • Net product revenue rose 34% year-over-year to exceed $91 million.
  • Full-year 2026 revenue guidance is now set at $385 million to $390 million.

Net product revenue surged 34% to more than $91 million, primarily driven by strong demand for its Recorlev treatment. This performance aligns well with the consensus estimate for earnings per share (EPS), which came in at $0.00. Positive investment sentiment surrounding Xeris is underscored by its current market capitalization of approximately $1.5 billion, highlighting the company’s potential for continued growth despite recent fluctuations in share price.

Solid Revenue Growth

The increase in revenue was largely attributed to a remarkable 81% year-over-year spike in Recorlev's net sales, which reached approximately $57 million. Comparatively, the second-quarter revenue from Recorlev in 2025 was just $31.4 million. Coexisting product lines such as Gvoke and Keveyis also contributed, with Gvoke revenue hovering around $22.5 million, albeit a slight decline from the previous year.

The overall revenue mix reflects Xeris Biopharma's strategic focus on enhancing its product offerings, which investors see as a positive indicator for sustainable growth moving forward. Strong consumer interest reinforces the company’s market position, providing a necessary buffer against more volatile market conditions.

Financial Whirlwind

Gross margin for Q2 improved to 86% from 82% year-over-year, primarily due to favorable product mix dynamics. This improvement translates into healthier margins that suggest operational efficiencies within the company. However, selling, general, and administrative expenses rose by $16.6 million, or 37%, indicating greater investment in commercial activities associated with the Recorlev expansion.

This significant loss was influenced by a one-time non-cash charge related to convertible notes, adding complexity for investors assessing short-term profitability.

Future Outlook

Xeris is tightening its full-year total revenue guidance to a range between $385 million and $390 million, signalling confidence in ongoing momentum and future performance. This event is likely to offer insights into potential growth areas within their pipeline, shaping investor expectations as they evaluate the company’s long-term trajectory.

Peers Moving on This News

  • Trulieve Cannabis Corp (TRLV) up 1.1%
  • Innoviva Inc (INVA) up 1.9%

Analysis based on the Form 8-K filed 6 August 2026; figures verified against the filing and live market data.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.